Wall Street Journal - July 26
July 26 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
- Immunity against the coronavirus is waning in people who were fully vaccinated with the shot made by BioNTech SE 22UAy.DE and Pfizer Inc PFE.N in January because of the rapidly spreading Delta variant, BioNTech Chief Executive Officer Ugur Sahin said, confirming data that emerged from Israel last week. Link
- The Biden administration is considering a new round of economic sanctions targeting Belarus and its authoritarian leader after a leading dissident appealed to U.S. officials for stronger U.S. action, according to participants in meetings last week in Washington. Link
- U.S. House of Representatives Speaker Nancy Pelosi named Republican Representative Adam Kinzinger from Illinois and critic of former President Donald Trump, to serve on a select committee investigating the Jan. 6 attack on the U.S. Capitol. Link
(Compiled by Bengaluru newsroom)
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.